Healthcare Large Cap Growth Stock Performance vs CRSP Index
Relative performance of selected healthcare companies versus the CRSP US Large Cap Growth Index, with baseline date set to January 1, 2020.
Home / Evidence & Performance / Healthcare stock performance
Relative Performance Table
Baseline date: January 1, 2020. Current column date: April 27, 2026.
| Ticker | 1 YR | 2 YR | 3 YR | 4 YR | 5 YR | 6 YR | Current |
|---|---|---|---|---|---|---|---|
| LLY | -9% | 35% | 162% | 283% | 362% | 549% | 398% |
| ISRG | 0% | 7% | 19% | 1% | 40% | 20% | -28% |
| VRTX | -29% | -74% | 16% | 22% | -39% | -57% | -74% |
| REGN | -8% | -4% | 78% | 77% | -31% | -57% | -69% |
| BSX | -58% | -80% | -13% | -38% | -25% | -54% | -133% |
| IDXX | 52% | 75% | 39% | 41% | -66% | -9% | -57% |
| DXCM | 31% | 71% | 95% | 59% | -80% | -143% | -158% |
| ALNY | -25% | -27% | 88% | 3% | -19% | 80% | -6% |
| RMD | -1% | -7% | 19% | -55% | -76% | -110% | -129% |
| EW | -19% | -6% | -19% | -68% | -127% | -154% | -162% |
| WST | 50% | 135% | 40% | 64% | -6% | -83% | -69% |
| MTD | 4% | 37% | 67% | -15% | -70% | -91% | -111% |
| VEEV | 53% | 5% | -3% | -33% | -75% | -108% | -158% |
| A | 1% | 12% | 60% | -4% | -66% | -106% | -136% |
| STE | -12% | -13% | 8% | -22% | -87% | -97% | -124% |
| TMO | 6% | 31% | 55% | 1% | -63% | -86% | -126% |
| WAT | -32% | -15% | 33% | -26% | -64% | -102% | -138% |
Quick takeaways
Relative to the CRSP US Large Cap Growth Index, LLY is a clear standout across longer windows and the current period. Most other names in this snapshot are currently below index performance, with a broad pattern of negative relative values in 5-year, 6-year, and current columns.
The table suggests a widening dispersion story: a few companies have materially outperformed in selected periods, while many names have lagged the index over longer horizons.
Related case studies
- Cigna's GLP-1 Study and Report
- VillageMD's VBC Model and Effectiveness
- Agilon's Model Helps Preserve Access to Primary Care
For more granular data, more recent data, or scientific analysis support, please email us.